PPT-Safety and Efficacy of Daclatasvir

Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Genotype 3 Infection Interim Results of a Multicenter European Compassionate Use Program Welzel TM. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. . + . Sofosbuvir. in Genotype . 3. ALLY-3 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Nelson DR, . et al. . . Hepatology. 2015;61:1127-35.. Source: . Nelson DR, et al. . 1. 1. http://www.accessdata.fda.gov/cdrh_docs/pdf/P980048b.pdf. The . views and opinions expressed in the following PowerPoint slides are those of . the individual . presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, . + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles DL, . et al. . N Engl J Med. 2015;373:714-25.. Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.. Field Program Assistant. IR-4 Western Region. . Western Region Ornamental Program. Overview of the program. Participation. Specifics of 2010 and 2011 research. Strengths and challenges. . WR Ornamental Program 2010-11. Changing Landscape of Therapeutic Options. Burden of AD in Adults. Dupilumab Phase 3 Trials. Study Design. Dupilumab Phase 3 Trials. Primary Efficacy Data. Dupilumab Phase 3 Trials. Secondary Efficacy Data. antiretroviral therapy for HIV-1:. a meta-analysis. Frederick J. Lee. 1. , Janaki Amin. 2. , Andrew Carr. 1. Centre for Applied Medical Research, St Vincent. ’. s Hospital . 1. Kirby Institute, University of New South Wales . . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. Emily Ellsworth, . PharmD. & Janna Hawthorne, . PharmD. UAMS College of Pharmacy. Objectives:. Explain . the pathophysiological rationale for the off-label utilization of six selected medications: . -. Beclabuvir in GT1 Patients without Cirrhosis. UNITY-1 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Poordad F, . et al. . JAMA 2015;313:1728-35.. Source: . Poordad F, et al. JAMA 2015;313:1728-35.. Alfonso Iorio, MD, PhD. Health Information Research Unit & Hemophilia Program. McMaster. University. Canada. Alfonso Iorio. Baxter . (Bayer, . Biogen. Idec, . NovoNordisk. , Pfizer . - No conflicts). Consultant Pediatrcian,Pedicare, Ratu Road,rch_sssidana@rediffmail.com. Alleviation of Pain Associated double-blind, placebo-controlled study with open-label extension. Atul Deodhar, MD. Oregon Health & Science University. Portland, OR, USA. Key message. Upadacitinib – a JAK1 inhibitor – showed sustained and consistent efficacy over 1 year in AS patients.. Ointment,. a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults. Paller. A, . Wynnis. T, . Lebwohl. M, et al.. http://www.jaad.org/article/S0190-9622(16)30330-9/abstract.